Abstract:Clinical trials have demonstrated that concurrent administration of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with chemotherapy agents does not improve overall survival in patients with non-small-cell lung cancer. Autophagy might play an important role in the resistance to EGFR-TKIs and/or chemotherapy agents. In the present study, we found that a combination of gefitinib and cisplatin generated antagonistic effects in EGFR-TKI-sensitive cells and that previously inhibiting autophagy by chloroquine could produce synergistic effect by increasing apoptosis.Background: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). In the present study, the role of autophagy in the combination of gefitinib and cisplatin on EGFR-TKI-sensitive human lung cancer cell line was investigated. Moreover, whether simultaneous autophagy inhibition treatment increases the antitumor activity was explored. Materials and Methods: The PC9 cell was exposed to either gefitinib or cisplatin alone or together. Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The cytotoxic interaction between gefitinib and cisplatin was determined using coefficient of drug interaction (CDI) analysis. The cell cycle distribution and apoptosis were measured using flow cytometry. Alterations in the autophagy and apoptosis signaling pathway were measured using Western blot assays. Results: Coadministration of gefitinib and cisplatin resulted in antagonistic activity to tumor cell proliferation. However, the addition of chloroquine (CQ), an autophagy inhibitor, overcame the antagonistic effects, as demonstrated by CDI analysis and Annexin V-FITC/propidium iodide (PI) assays. In addition, gefitinib administration led to cell G1 phase arrest, which might have contributed to the antagonistic activity between gefitinib and cisplatin. However, the addition of CQ did not deregulate cell cycle arrest, indicating that other mechanisms might be involved. The Annexin V-FITC/PI assays showed that the addition of CQ significantly the increased the ratio of apoptosis cells. Also, immunoblotting assays exhibited increased Bax and decreased Bcl-2, suggesting that autophagy inhibition by CQ could increase cell apoptosis and thus overcome the antagonistic effects. Conclusion: The combination of gefitinib with cisplatin generates antagonistic effects on EGFR-TKI-sensitive cells. However, inhibiting autophagy produces a synergistic effect, suggesting that gefitinib and cisplatin combined with an autophagy inhibitor (especially CQ) might be a beneficial strategy to overcome the antagonistic effects between EGFR-TKIs and chemotherapeutic agents. (C) 2015 Elsevier Inc. All rights reserved.

Inhibition of DNA‑PK by Gefitinib Causes Synergism Between Gefitinib and Cisplatin in NSCLC

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Gefitinib Sensitization of Cisplatin-Resistant Wild-Type EGFR Non-Small Cell Lung Cancer Cells

Synergistic Effect of Gefitinib and Cisplatin on Proliferation of Lung Cancer Cell Line

P2-155: STI-571 inhibits the growth of non-small cell lung cancer cell and intensifies the cisplatin effect in vitro

EP1.03-11 Mechanisms of Gefitinib Plus Pemetrexed on Human Non-Small Cell Lung Cancer

Gefitinib-Resistance is Related to Bim Expression in Non-Small Cell Lung Cancer Cell Lines

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non–Small-Cell Lung Cancer Cells

Gefitinib Synergizes With Irinotecan To Suppress Hepatocellular Carcinoma Via Antagonizing Rad51-Mediated Dna-Repair

Induced IGF-1R Activation Contributes to Gefitinib Resistance Following Combined Treatment with Paclitaxel, Cisplatin and Gefitinib in A549 Lung Cancer Cells.

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.

Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.

Synergistic anticancer effects of ginsenoside CK and gefitinib against gefitinib-resistant NSCLC by regulating the balance of angiogenic factors through HIF-1α/VEGF

In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.

Combination of Cetuximab and Gefitinibto Therapy Non-Small Cell Lung Cancer(nsclc) in Vitro

Enhanced Interaction Between Natural Killer Cells and Lung Cancer Cells: Involvement in Gefitinib-Mediated Immunoregulation

Metformin Sensitizes Cisplatin-induced Apoptosis Through Regulating Nucleotide Excision Repair Pathway in Cisplatin-resistant Human Lung Cancer Cells

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

Inhibitory effect and mechanism of gefitinib combined with metformin on EGFR-TKI intrinsic resistant NSCLC H1975 cells

Inhibition of PDGFR by CP-673451 Induces Apoptosis and Increases Cisplatin Cytotoxicity in NSCLC Cells Via Inhibiting the Nrf2-mediated Defense Mechanism.

A Novel Strategy of EGFR‑TKI Combined Chemotherapy in the Treatment of Human Lung Cancer with EGFR‑sensitive Mutation.